EXCLUSIVE: Hedge funder Kyle Bass is at war with big pharma, but he's long this one pharma stock
REUTERS/Brendan McDermid
Perrigo (PRGO) is now Hayman Capital's second largest equity position.
This is significant because Bass has been at war with the US pharmaceutical industry since the beginning of this year.
So far this year he's filed 13 inter partes review (IPR) petitions with the US Patent and Trademark Office challenging the patents of six publicly-traded pharma companies.
It's part of a new "short activist strategy" where Bass writes an IPR challenging the validity of a patent, while also shorting the company's stock. For this, Bass has even set up a separate pharmacy vehicle within his fund. The idea is that this will end "pay for delay" for drugmakers and ultimately lower drug prices.
Bass is scheduled to speak at the SALT Conference in Las Vegas. We'll be covering the event, so be sure to check back for updates.
- Tabu to work in Hollywood again, bags pivotal role in international series 'Dune: Prophecy'
- Digital Marketing for E-Commerce
- Indian stocks in green for second day after heavy sell-off
- Asia to contribute 60 pc of global growth in 2024: IMF official
- India's retail inflation eases marginally in April; here's what experts have to say
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market